Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Citra Anticoagulants is a specialized medical company focused on the development and manufacturing of anticoagulant solutions for vascular access and catheter maintenance. Based in the Netherlands, the company is best known for its Citra-Lock product range, which utilizes trisodium citrate in various concentrations (4%, 30%, and 46.7%) to prevent catheter-related complications. These products are primarily used in hemodialysis and intensive care to maintain catheter patency and reduce the risk of catheter-related bloodstream infections (CRBSI). The company's solutions are recognized for their efficacy in biofilm reduction and as a safer alternative to heparin-based locks. Citra Anticoagulants operates internationally, supporting healthcare providers in nephrology and vascular medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Citra Anticoagulants.